Loading…
Back To Schedule
Wednesday, June 28 • 10:30am - 11:30am
What Can ICH Bring to the Future of Model-Informed Drug Development (MIDD)?

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session
Level: Intermediate

MIDD can enhance the efficiency of drug development and regulatory decision-making. The ICH M15 guideline aims to enable the further integration and consistent use of MIDD. This session will cover the associated objectives, scope, and priorities.

Learning Objectives

Discuss current approaches, best practices, and future opportunities to enhance global drug development and regulatory decision-making through the use of model-informed approaches; Identify aligned positions from the ICH M15 IWG.

Chair

Erin Greene, JD

Speakers
avatar for Erin Greene

Erin Greene

US Lead, Global Regulatory Policy and Innovation, Takeda, United States
Experienced leader in Global Regulatory Policy and Intelligence with a demonstrated history of working in the pharmaceutical and healthcare industries. Graduated from American University, Washington College of Law with an emphasis on FDA regulation and health law and policy.

Wednesday June 28, 2023 10:30am - 11:30am CDT
TBD Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA
  06: TranslationalScience-PrecisionMedicine, Session